Cancer research moves fast. We make it understandable.
In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective…
Primary source cited
Last reviewed
In the randomized, phase 3 ENGOT-ov65/KEYNOTE-B96 trial, adding pembrolizumab to paclitaxel chemotherapy significantly improved BOTH progression-free survival (8.3 vs 7.2 months) AND overall survival (18.2 vs 14.0 months) in patients…
Primary source cited
Last reviewed
An investigational alpha-lactalbumin-targeted vaccine, developed by Anixa Biosciences with Cleveland Clinic, was reported to be safe and to induce a protocol-defined immune response in 74% of participants across all three…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
Primary source cited
Last reviewed
In the MZL cohort of the single-arm, phase 2 TRANSCEND FL trial, lisocabtagene maraleucel -- a CD19-directed CAR T-cell therapy -- produced an intent-to-treat overall response rate of 84.4% and…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 KEYNOTE-689 trial, adding pembrolizumab before and after surgery to standard treatment significantly extended event-free survival in patients with resectable, locally advanced, PD-L1-positive head and…
Primary source cited
Last reviewed
In the randomized, phase 3 BRUIN-CLL-321 trial, pirtobrutinib -- the first and only non-covalent (reversible) BTK inhibitor -- significantly extended progression-free survival compared with standard chemoimmunotherapy options in patients with…
Primary source cited
Last reviewed
In cohort 1 of the single-arm, phase 2b HERIZON-BTC-01 trial, zanidatamab -- a bispecific antibody that binds two separate sites on the HER2 protein -- produced a confirmed objective response…
Primary source cited
Last reviewed
In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the…
Primary source cited
Last reviewed